The kratom product landscape has changed dramatically over the last few years. A decade ago, “kratom” in the United States meant leaf powder or capsules — dried Mitragyna speciosa sold as a botanical supplement. Today, the fastest-growing kratom category at smoke shops, gas stations, and online retailers is concentrated 7-hydroxymitragynine — tablets, gummies, lozenges, and liquid shots that contain far more 7-OH than the plant naturally produces. This distinction is the single most important thing to understand if you’re weighing your own use or helping someone else.
Drug identity
A 7-OH tablet or gummy from a smoke shop is a different, more concentrated drug than a kratom leaf — even though both are sold as “kratom.”
Kratom is Mitragyna speciosa, a tropical tree in the coffee family. Its leaves hold 50+ alkaloids, but only two matter clinically: mitragynine and 7-hydroxymitragynine (7-OH). Concentrated 7-hydroxymitragynine products isolate the second one and deliver it at doses whole-leaf kratom never reaches.
Whole-leaf kratom
The plant
Mitragynine by dry leaf weight — the most abundant alkaloid in the leaf.
7-OH by dry leaf weight — present, but tiny.
- In whole leaf, mitragynine does most of the work.
- A slower onset and the broader alkaloid mix produce milder effects than a pure opioid.
Concentrated 7-OH
The isolated compound
Higher per gram than whole leaf, once manufacturers isolate the 7-OH.
Delivered at milligram / multi-milligram doses in tablets, gummies, lozenges, and liquid shots.
- 7-OH is a substantially more potent mu-opioid agonist than mitragynine — it binds more tightly and activates the receptor more strongly.
- At those doses it is behaving like a concentrated opioid agonist, not like leaf kratom.
The shared mechanism
Both mitragynine and 7-OH act on the mu-opioid receptor — the same receptor as prescription opioids, heroin, and fentanyl. That is why kratom produces opioid-like effects and physical dependence.
The Botany: Kratom Contains 50+ Alkaloids, Including 7-OH
Kratom (Mitragyna speciosa) is a tropical tree in the coffee family, native to Southeast Asia. Its leaves contain more than 50 alkaloids — plant-derived compounds with biological effects — but only two matter much clinically: mitragynine and 7-hydroxymitragynine (7-OH). Both act on the mu-opioid receptor in the brain, which is the same receptor targeted by prescription opioids, heroin, and fentanyl. That shared mechanism is why kratom produces opioid-like effects and why regular use can cause opioid-type physical dependence and withdrawal.
Mitragynine is the most abundant alkaloid in the leaf — usually around 1-2% of dry leaf weight. 7-OH is present too, but in very small amounts — typically under 0.05% of dry leaf weight, sometimes as a fresh-leaf metabolite or produced in small quantities during drying. In whole-leaf kratom, mitragynine is doing most of the work, and the slower onset + broader alkaloid mix tends to produce milder effects than a pure opioid would.
Why 7-OH Matters Disproportionately to Its Amount
Here’s the pharmacology wrinkle: despite making up a tiny fraction of total alkaloids, 7-OH is a substantially more potent mu-opioid agonist than mitragynine. Lab studies in animal models suggest 7-OH binds more tightly and activates the receptor more strongly. The FDA, in its July 2025 assessment, specifically cited animal studies showing dependence and abuse potential consistent with classical opioids.
In unprocessed leaf, 7-OH’s potency is moderated by the tiny quantities present and by mitragynine’s more dampening effect profile. Strip 7-OH out of the leaf and concentrate it alone — as a tablet, a gummy, a shot — and the pharmacology changes categorically. A product that delivers pure 7-OH at milligram or multi-milligram doses is no longer behaving like leaf kratom. It’s behaving like a concentrated opioid agonist.
How Concentrated 7-OH Products Are Made
Manufacturers extract and isolate 7-OH using standard chemistry methods — solvent extraction, purification, and recrystallization — to create products with 7-OH content that can be hundreds of times higher per gram than whole leaf. Some products are described on the label as containing specific milligram amounts of 7-OH per serving, or multiples of “1x/2x/5x extract,” though labeling accuracy in the unregulated market is notoriously inconsistent.
A few kratom industry groups and some state regulators have specifically flagged concentrated 7-OH products as outside the traditional kratom market, arguing that a whole-leaf regulatory framework should not cover them. The FDA, from the other direction, has singled out concentrated 7-OH for Schedule I scheduling precisely because it’s pharmacologically different from whole leaf. Both positions agree on the core point: concentrated 7-OH is not the same substance as the traditional product.
Newer Designer Analogs: MGM-15, MGM-16, and Pseudoindoxyl
Isolating natural 7-OH is one step; engineering it is the next. Since early 2025, semi-synthetic analogs built from 7-OH have begun appearing in the U.S. market — compounds modified to activate the opioid receptors more strongly and for longer than 7-OH itself. The two most often named are MGM-15 and MGM-16.
MGM-15 (chemical name dihydro-7-hydroxymitragynine) is a derivative of 7-OH first described in 2014 medicinal-chemistry research and, per a 2025 peer-reviewed review, a more potent mu- and delta-opioid receptor agonist than 7-OH. MGM-16, its fluorinated counterpart, is more potent still — many times stronger than morphine in animal studies. Neither occurs in natural kratom leaf; both are laboratory products, usually sold online as “research-only” powder. A forensic laboratory first identified MGM-15 in seized U.S. material in September 2025.
There are no human safety or withdrawal studies on MGM-15 specifically. The concern comes from its opioid-receptor mechanism; there is no dependence data yet, so no one can publish a reliable withdrawal timeline for it. The earliest documented U.S. appearances were in the Northeast and Ohio — which has since scheduled dihydro-7-OH (MGM-15) by name as a Schedule I substance, effective May 2026. MGM-15 had not been reported in Tennessee or North Georgia in published surveillance, though we have begun seeing these products in our Chattanooga clinic. Regulators are now naming it directly: in June 2026 the Missouri Attorney General named MGM-15 in a settlement halting its sale, and bans written to cover “7-OH and its derivatives” are designed to reach analogs like it. Because MGM-15 and MGM-16 act on the same mu-opioid receptors as 7-OH, the same buprenorphine-based treatment applies; for how we treat dependence on it, see our MGM-15 & Oxonol treatment page.
Leaf vs. concentrate
Why withdrawal from 7-OH concentrates is harder
Patients dependent on concentrated 7-OH consistently describe withdrawal that is more intense and more relapse-prone than withdrawal from whole-leaf kratom. The pharmacology is consistent with that experience.
Milder withdrawal
Whole-leaf kratom withdrawal
Milder, mixed-alkaloid profile
Harder withdrawal
Concentrated 7-OH withdrawal
Strong, high-potency mu-agonist
A milder, mixed-alkaloid profile produces less receptor adaptation, so the drop during withdrawal starts from a lower point.
Regular high-dose exposure to a strong mu-agonist produces more receptor adaptation than a milder, mixed-alkaloid profile. The gap during withdrawal is correspondingly steeper.
A longer duration of effect means blood levels rise and fall less abruptly, so early withdrawal tends to build more gradually.
Concentrated 7-OH is typically dosed multiple times per day because of its shorter duration of effect. Blood levels rise and fall frequently, and withdrawal can begin within hours of a missed dose.
Anxiety, insomnia, and cravings still occur, but tend to be reported as more manageable than the concentrate.
More severe anxiety, insomnia, and cravings — reported frequently enough that clinicians plan for it. The first week after stopping 7-OH concentrates is often described by patients as the hardest week of their lives.
A single use during a taper is less likely to snap the whole cycle back into place as fast.
Because the product is fast-onset and high-potency, a single use after a partial taper often resets the cycle completely. This is why clinicians generally recommend MAT over self-taper for 7-OH dependence.
Using concentrated 7-OH?
The deeper tolerance, faster onset, harder symptoms, and quicker rebound are why a self-taper off concentrated 7-OH so often stalls where a whole-leaf kratom taper might hold. For 7-OH withdrawal at this level, our clinicians generally start patients on MAT (buprenorphine) instead of a self-taper, so the taper is medically managed.
For a day-by-day picture of what the withdrawal arc typically looks like, see our article on the kratom withdrawal timeline. The mechanisms described there apply to both leaf and 7-OH, but the intensity on the 7-OH side is typically worse.
The FDA’s July 2025 Action: What It Actually Targets
On July 29, 2025, the FDA formally recommended to the DEA that concentrated 7-OH products be scheduled as Schedule I under the Controlled Substances Act. Two weeks earlier, on July 15, the FDA had issued warning letters to seven companies marketing 7-OH products (Shaman Botanicals, My Smoke Wholesale, RRR Trading / EDP Kratom, Thang Botanicals / 7ΩHMZ, Royal Diamond Imports / Roxytabs, Hydroxie LLC, and 7Tabz Retail), citing unapproved new drug claims and misbranding.
The regulatory timeline
From Drug of Concern to a Tennessee ban
Federal regulators and the State of Tennessee have moved on 7-OH over the past 18 months. Here is the sequence, from the DEA's 2025 designation through the Tennessee kratom ban that is now in effect. Every date links to the primary source.
-
Jan 22, 2025
DEA
The DEA formally designated kratom and 7-hydroxymitragynine as “Drugs of Concern” — a classification signaling abuse potential without scheduling the substance.
-
Jul 15, 2025
FDA
The FDA issued warning letters to seven companies marketing 7-OH products, citing unapproved new drug claims and misbranding.
-
Jul 29, 2025
FDA → DEA
The FDA formally recommended to the DEA that concentrated 7-OH products be scheduled as Schedule I under the Controlled Substances Act.
-
Apr 16, 2026
-
May 7, 2026
Tennessee
Signed into law by Gov. Bill Lee as Public Chapter 950.
Enacted -
Jul 1, 2026Ban in effect
Tennessee
Effective date. Tennessee becomes the eighth U.S. state to fully ban kratom — and 7-OH, which falls under the bill's definition. The ban is now in effect.
The FDA action is a recommendation
The FDA's July 29 action is a recommendation, not law. The DEA reviews it through its own rulemaking, including a public-comment period, before any final scheduling. That process can take months to years.
The Schedule I scope is narrow
The Schedule I recommendation targets concentrated 7-OH products. Natural whole-leaf kratom was not targeted by the Schedule I recommendation.
Coverage on this page: FDA Schedule I · 7-OH ban · DEA Drugs of Concern · HB1649 · Public Chapter 950 · Tennessee kratom ban.
At the state level, Tennessee’s HB1649/SB1656 (“Matthew Davenport’s Law”) passed both chambers on April 16, 2026 and was signed into law by Gov. Bill Lee on May 7, 2026 (Public Chapter 950), effective July 1, 2026 — making Tennessee the eighth U.S. state to fully ban kratom (and 7-OH, which falls under the bill’s definition). The competing regulate-and-cap bill, HB2594, did not advance. See our Tennessee kratom laws article for the detailed picture.
Neighboring states are moving in different directions. Georgia maintains a regulated-legal framework with age-21 restrictions and processor registration requirements, though HB968 is a proposal that would shift GA toward the Alabama model. Alabama has classified kratom as a Schedule I controlled substance since 2016 and escalated enforcement with a statewide Attorney General cease-and-desist order in March 2026. For the full U.S. picture, see our kratom laws by state 2026 tracker; for the federal 7-OH scheduling timeline, see Is 7-OH banned yet?.
What This Means If You’re Using Concentrated 7-OH
The regulatory wave is one reason to consider stopping, but it’s not the most important one. The more compelling reason is the health picture: concentrated 7-OH is producing opioid-type dependence severe enough that the Tennessee Department of Health now reports withdrawal as the #1 reason Tennesseans visit the emergency room after using kratom (30.4% of kratom ER visits, up sharply in 2025). Kratom-involved ER visits in Tennessee doubled from 2024 to 2025 (77 → 153), and the fastest-growing segment is men and adults 18–44 — the demographic most likely to be using concentrates. Nationally, the CDC’s March 2026 MMWR report documented a 1,200% increase in kratom-related calls to U.S. poison centers from 2015 to 2025, with the most severe outcomes occurring in multi-substance exposures.
If any of the following describe your use, the clinical case for seeking treatment is strong:
- You’ve escalated from lower-potency products to 7-OH tablets, gummies, or shots.
- You’re dosing multiple times per day to avoid early withdrawal.
- You’ve tried to stop and returned to use within days.
- Product availability (particular brand, particular dose) is shaping your day.
- You’ve experienced withdrawal symptoms that surprised you — aches, anxiety, GI distress, insomnia within hours of skipping a dose.
Concentrated 7-OH and its analogs respond to the same buprenorphine treatment as leaf kratom, because they act on the same opioid receptors. The one thing that changes is the timing of your first dose, which the clinic works out with you from your withdrawal score.
See your treatment optionsTreatment Works the Same Way It Does for Leaf Kratom
The same medication-assisted treatment that works for whole-leaf kratom dependence works for concentrated 7-OH dependence — because the underlying mechanism is the same mu-opioid receptor adaptation. Suboxone (daily sublingual), Sublocade (monthly injection), and Brixadi (weekly or monthly injection) are all buprenorphine-based and clinically appropriate for 7-OH-type dependence.
What differs for 7-OH patients is often the intake timing — our providers plan the induction window carefully because abrupt transitions from high-potency concentrate to buprenorphine can trigger precipitated withdrawal if the timing is off. For the clinical details on how MAT handles kratom and 7-OH withdrawal, see our article on Suboxone for kratom withdrawal.
What to Do Next
If you or someone you care about is using concentrated 7-OH products and finding it hard to stop, call 423-498-2000 or submit a contact request. Same-week appointments are available at all four of our clinic locations across Tennessee and Georgia. The regulatory picture will keep shifting over the next year or two, but the treatment path is stable and works.
If a loved one is the one using these products, our guide on how to help a family member using kratom or 7-OH covers the warning signs, how to start the conversation, and how to get treatment underway now that Tennessee’s July 1 ban is in effect.
References
Primary regulatory and public-health sources cited in this article.
- U.S. Food and Drug Administration. “FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers” (Schedule I recommendation to DEA, July 29, 2025). [FDA]
- U.S. Food and Drug Administration. “FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine” (July 15, 2025). [FDA]
- U.S. Drug Enforcement Administration, Diversion Control Division. “Kratom Drugs of Concern designation” (January 22, 2025). [DEA]
- Tennessee Department of Health, Overdose Surveillance Program. “Kratom Overdose Trends in Tennessee” (Emerging Trends Brief, February 2026). [TDH]
- Centers for Disease Control and Prevention. “Increases in Kratom-Related Reports to Poison Centers — National Poison Data System, United States, 2015–2025.” MMWR 2026;75(11). [CDC MMWR]
- Tennessee General Assembly. HB1649 / SB1656 (“Matthew Davenport’s Law”), signed into law May 7, 2026 (Public Chapter 950). [LegiScan HB1649] / [LegiScan SB1656]
- Tennessee General Assembly. HB2594 (kratom regulation alternative; did not advance). [LegiScan]
- WSMV4 News, Nashville. “Tennessee kratom ban bill heads to Gov. Bill Lee’s desk” (April 17, 2026). [News]